BioMarin Secures Final French FDI Clearance for Amicus Therapeutics Merger, Closing Expected April 27
Summary
BioMarin Pharmaceutical Inc. announced it has received the final regulatory clearance for its merger with Amicus Therapeutics, with the closing now anticipated on April 27, 2026.
Key Events
-
Final Regulatory Hurdle Cleared
BioMarin Pharmaceutical Inc. received final foreign direct investment clearance from the French Ministry of Economics and Finance for its merger with Amicus Therapeutics, Inc.
-
Merger On Track for Imminent Close
This clearance satisfies the final condition to the Merger, with the closing now expected on April 27, 2026, following the initial agreement on December 19, 2025.
Analysis
This 8-K filing marks a critical milestone for BioMarin's previously announced $4.8 billion acquisition of Amicus Therapeutics. The receipt of final French foreign direct investment clearance removes the last significant regulatory hurdle, paving the way for the merger to close as early as April 27, 2026. This development de-risks the transaction and provides certainty regarding the integration of Amicus, which was a major strategic move detailed in BioMarin's recent 10-K filing.
At the time of this filing, BMRN was trading at $53.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $50.76 to $66.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.